Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 414 of 6351
-
Can a radioactive 'Smart Bomb' target tough tumors?
Disease control Recruiting nowThis is an exploratory clinical study evaluating the safety, tolerability and biodistribution characteristics of 177Lu-FAP-VG11 injection in patients with FAP-positive advanced solid tumours.
Early phase 1 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could direct heart pacing beat standard therapy for heart failure?
Disease control Recruiting nowThe NORDIC-CSP trial is an investigator-initiated, blinded, nordic RCT aimed at evaluating whether using direct pacing of the HIS bundle (HIS)-pacing or left bundle branch (LBB) pacing is superior to conventional biventricular pacing in reducing the incidence of the composite end…
Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Experimental brain tumor injection shows promise in early trial
Disease control Recruiting nowThe goal of this clinical trial is to evaluate the safety and efficacy of JL15003 Injection in subjects with recurrent glioblastoma (rGMB).
Phase 1/2 • Sponsor: Jecho Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Hope for kids with rare brain cancer: new drug combo trial launches
Disease control Recruiting nowThis is a multi-treatment arm study that will be conducted through the Pacific Pediatric Neuro-oncology Consortium (PNOC).The study will assess the safety and efficacy of novel therapies and combinatorial strategies for participants with recurrent or progressive ATRT.
Phase 2 • Sponsor: Sabine Mueller, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
AI eye on lung cancer: new study tests smart screening for High-Risk families
Diagnosis Recruiting nowThis research is being done to determine if an image-based deep learning model (Sybil) can accurately predict the likelihood of future lung cancer based on chest computed tomography (CT) imaging from individuals with a family history of lung cancer.
Sponsor: Massachusetts General Hospital • Aim: Diagnosis
Last updated Aug 27, 2026 00:00 UTC
-
Immunotherapy-Chemo cocktail aims to boost esophageal cancer surgery success
Disease control Recruiting nowThis clinical trial aims to preliminarily evaluate the efficacy and safety of adebrelimab combined with albumin-bound paclitaxel and carboplatin as neoadjuvant therapy for borderline resectable locally advanced esophageal squamous cell carcinoma (ESCC). The primary research objec…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New heart device aims to seal Stroke-Causing hole
Disease control Recruiting nowThe goal of this clinical trial is to test a new heart device called P3 Occluder System in patients who have a small opening between the upper chambers of the heart (called a Patent Foramen Ovale or PFO) and have experienced a stroke that may be related to this heart opening. The…
Sponsor: Recross Cardio, Inc. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Could a dab of liquid under the tongue replace weekly weight-loss shots?
Disease control Recruiting nowThis study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general. GLP-1 is a gut-derived hormone that induces satiatio…
Phase 4 • Sponsor: Gila Therapeutics, Inc. • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a single antibody turn down the immune storm in ARDS?
Disease control Recruiting nowHospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be followed for 28 days. The primary outcome is the day 4 oxygenation index assessed as a continuous measure.
Phase 2 • Sponsor: Implicit Bioscience • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Which dialysis method offers the best life and survival?
Knowledge-focused Recruiting nowThis is a multicenter, prospective, observational real-world study designed to evaluate clinical effectiveness, quality of life, and healthcare resource utilization in patients with end-stage renal disease (ESRD) initiating dialysis therapy in China. Participants will be grouped…
Sponsor: Vantive Health LLC • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
AI chatbot could help gynecologic cancer survivors reclaim sexual health
Symptom relief Recruiting nowThis study aims to develop the LillyBot Smart Sexual Health Consultation System, designed to meet the sexual health learning and consultation needs of gynecological cancer (GC) patients in Taiwan. Grounded in the Transtheoretical Model (TTM), this system integrates AI chatbot tec…
Sponsor: Chang Gung Memorial Hospital • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
Could a lower drug dose be safer and just as effective for kids with rare tumor?
Disease control Recruiting nowThis randomized clinical trial evaluates if low-dose sirolimus (target trough 4-8 ng/mL) combined with prednisolone is noninferior in efficacy but superior in safety compared to standard high-dose sirolimus (target trough 10-15 ng/mL) combined with prednisolone in pediatric patie…
Phase 2/3 • Sponsor: Yi Ji • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Targeted combo aims at tough lymphoma subtype
Disease control Not yet recruitingThis is a single-center, single-arm, prospective study aimed at evaluating the efficacy and safety of orelabrutinib combined with an induction regimen followed by monotherapy maintenance in patients with MCD subtype diffuse large B-cell lymphoma (DLBCL). The primary endpoint is t…
Phase 2 • Sponsor: Ou Bai, MD/PHD • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New pill aims to wipe out lingering lymphoma cells after remission
Disease control Recruiting nowThis is a prospective, multicenter, single-arm, open-label phase 2 study designed to evaluate the efficacy and safety of chidamide maintenance in adults with newly diagnosed double-expressor diffuse large B-cell lymphoma (DLBCL) who achieve complete response after induction thera…
Phase 2 • Sponsor: Rong Tao • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on tough lung cancer
Disease control Recruiting nowThis is a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recommended dose(s) (RD) and to evaluate the safety, tolerability and preliminary efficacy of DJI136.
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Emergency rooms may become a frontline for HIV prevention in teens
Prevention Recruiting nowScreen2Prevent is a study intended to improve HIV prevention and detection through implementation and evaluation of three different broad-scale HIV screening approaches a) targeted, b) universally offered opt-in, and c) universally offered opt-out in Emergency Departments (EDs) b…
Sponsor: Westat • Aim: Prevention
Last updated Aug 19, 2026 00:00 UTC
-
Gene therapy trial aims to fix heart muscle in rare genetic disease
Disease control Recruiting nowThis study is designed to evaluate the safety and tolerability of NVC-001 in adults with LMNA-related dilated cardiomyopathy (LMNA-DCM). The study will also assess exploratory measures of efficacy.
Phase 1/2 • Sponsor: Nuevocor Pte. Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug cocktail aims to stop head and neck cancer from coming back
Disease control Recruiting nowThis is a multicenter, randomized, controlled, Phase II clinical study designed to evaluate the efficacy and safety of neoadjuvant and adjuvant therapy with vebikotamab combined with Pucotenlimab compared to standard treatment in patients with locally recurrent resectable head an…
Phase 2 • Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New combo therapy aims to stop bile duct cancer return after surgery
Disease control Recruiting nowThis is a multicenter, open-label, single-arm, prospective Phase II clinical trial. The study enrolls patients with extrahepatic cholangiocarcinoma or gallbladder carcinoma who have undergone curative resection and harbor high-risk recurrence factors, including: 1) narrow resecti…
Phase 2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug duo targets deadly brain cancer in early trial
Disease control Recruiting nowThis is a phase IB/II, open-label study evaluating CTX-009 as monotherapy and in combination with CTX-471. The study evaluates the safety and efficacy of the monotherapy and the combination in patients with recurrent glioblastoma. The study tests the hypothesis that treatment wit…
Phase 1/2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC